Amorfix provides corporate update on therapeutics program for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrigs disease)

Monitor this Company


/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TSX Venture: AMF

TORONTO, March 23 - - Amorfix Life Sciences Ltd. (TSX-V:AMF), a
theranostics company developing diagnostics and treatments for aggregated
misfolded protein (AMP) related diseases, today announced Dr. Neil Cashman,
Chief Scientific Officer of Amorfix will be presenting a study entitled
"Immunotherapy of ALS" at the ALS Canada Research Conference in Toronto, on
March 25, 2007. The study is based on pioneering work by Dr. Cashman and shows
for the first time promising animal studies that a targeted immunotherapy
approach may lead to an effective treatment for this debilitating disease.
Dr. Cashman has long proposed that the misfolding and aggregation of
superoxide dismutase 1 (SOD1), which is known to occur in familial ALS
patients, is a principal agent in the death of motor neurons in all types of
ALS disease. He hypothesized, 5 years ago, that if the misfolded SOD1 could be
recognized and neutralized by the immune system prior to aggregation, the
disease could be effectively treated. The animal studies provide early but
provocative data supporting this approach.
These studies were conducted as part of the research collaboration with
Biogen Idec (NASDAQ: BIIB) of Cambridge, Massachusetts. The collaboration
includes an option for Biogen Idec to license the exclusive worldwide rights
to Amorfix's technology to develop and commercialize therapeutic products
directed against ALS.
"These results, while still very early, demonstrate the potential of
targeted immunotherapy as a novel approach for the effective treatment of
ALS," said Dr. George Adams, President and Chief Executive Officer of Amorfix.
"We continue to advance our therapeutic program for AMP diseases, specifically
in relation to our research collaboration with Biogen Idec targeting ALS.
There are a number of milestones remaining and we are making excellent
progress."
Amorfix is also announcing that it has filed an international patent
application entitled "Methods and Compositions to Treat and Detect
Misfolded-SOD1 Mediated Diseases." The Company is continuing to expand its
intellectual property estate based on initiatives generated by its
therapeutics research and development program.

About Amorfix

Amorfix is an emerging biotechnology company focused on the diagnosis and
treatment of brain-wasting diseases, where aggregated misfolded proteins
(AMPs) are prevalent. These include "prions", the infectious agents of the
Transmissible Spongiform Encephalopathies (TSE), such as BSE and variant CJD,
as well as degenerative diseases such as Alzheimer's Disease, ALS and
Parkinson's Disease. Amorfix is focused on discovering and commercializing
technologies to become the world leader on AMP diseases. The company will use
this knowledge to develop diagnostic kits, treatments and vaccines for AMP
diseases.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This information
release may contain certain forward-looking information. Such information
involves known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements should
not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs as well
as assumptions made by and information currently available to it as well as
other factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

%SEDAR: 00022789E


Monitor this Company :
You will receive an email alert whenever there is a news item concerning this company.
Name Your Company
Email Address Position/Role


2001 - 2016 Lexdon Business Library
About TrustBase
Privacy Policy